Peripheral lymphocytes are known to vary in number and percentage from birth until death. The first studies on the subject dealt with small sample sizes and a limited number of cell subsets were analysed ([@B25], [@B26], [@B24], [@B6], [@B3]). The development of new laboratory techniques, the discovery of different cell subsets and the use of various cell markers have led to a constant need to update previous reference values. Moreover, different variables have proved to interfere with normal ranges of all of these cell subsets.

Ethnic origin, genetics, gender and environmental factors have been shown to influence some immunologic indices, so that the development of reference values for populations of different backgrounds may be necessary to improve diagnosis and follow-up of individuals with chronic diseases and an altered immune system.

Previous studies have found that exclusively-breastfed infants had a higher thymic index than partially-breastfed or formula-fed infants as assessed by sonography ([@B8]). Additionally, CD8^+^ T cell numbers were higher among exclusively-breastfed children, who also had a higher thymic index ([@B9]). The authors speculated on the potential for both current and long-term immune-modulating effects of human milk on the developing immune system ([@B9]).

Because more intense and frequent modifications occur in the developing immune system, the paediatric age range is the period of life when more changes are observed. Hence, the need for immunologic reference values that do vary across the neonatal period, infancy, childhood and adolescence is undisputable.

In the present study, we have determined the distribution of lymphocyte subsets in healthy Brazilian neonates, infants, children, adolescents and adults.

SUBJECTS, MATERIALS AND METHODS
===============================

*Patients and study design* - This study was an observational, cross-sectional assessment of lymphocyte subsets in human immunodeficiency virus (HIV)-unexposed healthy children from birth to 49 years of age. The protocol was approved by the Ethical Committee of the Federal University of São Paulo (UNIFESP), in São Paulo, Brazil. All individuals or parents - in the case of individuals below 18 years of age - gave written informed consent prior to enrolment in the study.

Inclusion criteria were: neonatal weight of 2,500 g or more, having no chronic diseases or previous clinical findings suggestive of immune compromise (e.g., meningitis, pneumonia, repetitive acute upper respiratory infections or diarrhoea), having no acute disease in the previous seven days before blood collection, using no medication other than vitamins, not being pregnant and not being HIV-exposed.

Age strata were organised as follows: cord blood, one-91 days old (0-3 months), 92-182 days old (3-6 months), 183-364 days old (6-12 months), from the first birthday to the day before the second birthday (1-2 years), from the second birthday to the day before the sixth birthday (2-6 years), from the sixth birthday to the day before the 12th birthday (6-12 years), from the 12th birthday to the day before the 19th birthday (12-18 years) and from the 19th birthday to the day before the 49th birthday (19-48 years).

For each age strata, effort was made to have an equal distribution of male and female subjects.

Data regarding the period of exclusive and non-exclusive breastfeeding were also collected at study entry up to the 12-18 year age stratum.

Cord blood collection was performed in two neonatal units from hospitals associated with UNIFESP. Individuals from all other age strata were assessed at São Paulo Hospital and Centro Assistencial Cruz de Malta, in São Paulo. Four hundred and sixty-three subjects participated in the study, comprising a minimum of 50 individuals per age group.

*Blood collection* - Cord blood (10 mL) was collected from the umbilical vein. For all other age strata, a 5-mL blood sample of peripheral blood was collected. Samples were put into ethylenediamine tetraacetic acid-treated vacuum tubes for complete blood counts (CBC) and phenotypic analysis of peripheral blood mononuclear cell subsets using flow cytometry assays.

*CBC* - All samples were tested using ADVIA 120 automatic counter (Bayer HealthCare, Germany). When indicated, a slide smear was performed for manual count by a trained staff.

*Flow cytometry analysis* - Cord and peripheral blood mononuclear cells were assessed by flow cytometry (FACSCalibur, BD Biosciences, USA) within 18 h of blood collection and analysed using CellQuest software (BD Biosciences). Four-colour phenotypic characterisations were performed in fresh blood using a lyse-wash protocol. Appropriate isotype controls (IgG1-FITC, IgG1-PE, IgG1-APC, IgG2a-PE) (BD Biosciences) were used to evaluate non-specific staining. For each sample, multiparametric data were acquired for 10,000 events.

Cell numbers per cubic millilitre of blood were obtained using the lymphocyte counts from the CBC.

The following monoclonal antibody (MAb) (all from BD Biosciences) combinations were used: CD4^+^T lymphocytes and differentiation subsets using CD45RA and CCR7*.* Using CD3-APC, CD4-PerCP, CD45RA-FITC and CCR7-PE, T cell subsets were defined as naïve, CD3^+^CD4^+^CD45RA^+^CCR7^+^, central memory, CD3^+^CD4^+^CD45RA^-^CCR7^+^, effector memory, CD3^+^CD4^+^CD45RA^-^CCR7^-^, and effector, CD3^+^CD4^+^CD45RA^+^CCR7^-^ ([@B11]).

*CD4* ^*+*^ *T lymphocytes and differentiation subsets using CD45RA and CD27 -* Using CD3-APC, CD4-PerCP, CD45RA-FITC and CD27-PE, T cell subsets were defined as naïve, CD3^+^CD4^+^CD45RA^+^CD27^+^, effector memory, CD3^+^CD4^+^CD45RA^-^CD27^+^ and CD3^+^CD4^+^CD45RA^-^CD27^-^, and effector, CD3^+^CD4^+^CD45RA^+^CD27^-^ ([@B7]).

CD8^+^T lymphocytes were characterised in the same way for differentiation subsets by substituting CD4-PerCP MAb for CD8-PerCP MAb ([@B7], [@B11]).

*CD4* ^*+*^ *T lymphocyte activation* - Using CD3-APC, CD4-PerCP, CD38-FITC and CD25-PE, CD38 and CD25 expression were evaluated as the percentage of positive CD3^+^CD4^+^ T cells for each marker.

*CD8* ^*+*^ *T lymphocyte activation* - Using CD3-APC, CD8-PerCP and CD38-FITC, CD38 expression was evaluated as the percentage of positive CD3^+^CD8^+^T cells.

*CD8* ^*+*^ *T lymphocytes with cytolytic effector function* - Using CD3-APC, CD8-PerCP and CD56-PE, CD56 expression was evaluated as the marker associated with cytolytic function ([@B15], [@B16]).

*B lymphocytes -*Using CD3-APC and CD19-FITC, B lymphocytes were identified as CD3^-^CD19^+^ cells.

*Natural killer (NK) cells* - Using CD3-APC, CD45-PerCP, CD16-PE and CD56-PE, NK cells were quantified by the CD45^+^CD3^-^CD56^+^CD16^+^ phenotype.

[Fig. 1](#f01){ref-type="fig"} shows an illustrative example of flow cytometry plots used for data analysis.

Fig. 1: illustrative example of flow cytometry plots for data analysis. Lymphocytes were selected on the side scatter/forward scatter plot with a gate as shown in A. T cells were identified from the gate of lymphocytes as CD3+ (B), B cells, as CD3-CD19+ (C) and natural killer (NK) cells, as CD3-CD16+/CD56+ (D). CD4+ T cells were identified from the gate of lymphocytes as CD3+CD4+ (E) and then separated in differentiation subsets using CD45RA/CCR7 (F) or CD45RA/CD27 markers (G); CD38 and CD25 expression were evaluated on CD4+ T cells in H and I, respectively. CD8+ T cells were identified from the gate of lymphocytes as CD3+CD8+ (J) and then separated in differentiation subsets using CD45RA/CCR7 (K) or CD45RA/CD27 markers (L); CD38 and CD56 expression were evaluated on CD8+ T cells in M and N, respectively. Isotypic controls were employed to set the gates in F-I, K-N plots.

*Statistical analysis* - Data were analysed using Minitab 15.1 (Minitab, USA) and Stata 7.0 (Stata, USA). Percentiles (10th, median and 90th) of end-point distributions are based on percentiles of observed data. Comparison with Pediatric AIDS Clinical Trials Group P1009 (PACTG P1009) data ([@B19]) was performed by measuring the median 95% confidence intervals for each parameter within age strata from zero-three months up to 12-18 years and comparing them with median values from the corresponding data from [@B19]. The level of significance was set at p \< 0.05.

RESULTS
=======

Four hundred and sixty-three individuals participated in the study. The characteristics of study subjects are summarised in [Table I](#t01){ref-type="table"}. They reflect the Brazilian population, where the majority of children are exclusively breastfed during the first three or four months. After the introduction of formula or solid food, many are still partially breastfed during the second semester of life.

TABLE IDemographic data and breastfeeding information of study participants Cord blood0-3 months3-6 months6-12 months1-2 years2-6 years6-12 years12-18 years19-48 yearsAge strata (n)535150535055505051Feminine gender \[n (%)\]10 (18.9)19 (37.2)27(54)24 (45)23 (46)22 (40)29 (58)22 (44)25 (49)Exclusive breastfeeding at assessment \[n (%)\]NA39 (77)20 (40)\-\-\-\--NCPartial breastfeeding at assessment \[n (%)\]NA10 (20)14 (28)\-\-\-\--NCTotal exclusive breastfeeding time (mean ± SD) (months)NA\--3.6 ± 2.74.7 ± 2.53.5 ± 4.04.1 ± 2.94.2 ± 2.9NCTotal breastfeeding time (mean ± SD) (months)NA\--5.4 ± 2.88.8 ± 5.78.3 ± 9.712.7 ± 13.29.2 ± 9.5NCChildren with formula only from birth \[n (%)\]NA2 (4)NoneNone2 (1)6 (11)1 (0.5)5 (10)NC[^1]

[Table II](#t02){ref-type="table"} presents subset percentages of peripheral blood lymphocytes and [Table III](#t03){ref-type="table"} depicts cell subset counts of peripheral blood lymphocytes in different age strata from healthy Brazilian children, adolescents and adults.

TABLE IISubset percentages of peripheral blood lymphocytes in healthy Brazilian individualsSubset (%)Cord blood (53)0-3 months (51)3-6 months (50)6-12 months (53)1-2 years (50)2-6 years (55)6-12 years (50)12-18 years (50)Adults (51)CD339.6 (21.8-55)64.5 (55.5-71.2)58.5 (47.9-68.4)59.1 (51.8-68.5)62.8 (52.6-69.4)66.2 (57.1-72.7)68.2 (61.1-77.4)65.7 (53.3-75.3)65.2 (55.5-75.2)CD1915.2 (9.3-22)20.2 (7.7-27.8)31.1 (20.2-39.4)25.9 (16.4-35.7)23.8 (15.6-32.2)19.3 (13.3-26.7)14.7 (9.7-20.7)14.4 (10.3-21.5)12.4 (6.1-17.1)CD3^-^/16^+^56^+^18.2 (8.6-28.2)9.9 (5-15.5)7.1 (3.9-11)6.3 (3.8-14.4)5.9 (3.3-14.6)7.3 (7.8-16.1)9.7 (4.2-16.1)10.5 (3.9-18.4)12.5 (7-22.8)CD428.9 (11.4-40.3)44.1 (36.7-52.2)38.2 (27.9-47.2)37.6 (26.4-47.5)36.1 (26.1-47)37.7 (27.7-46.3)35.4 (28.5-44)38.1 (30.7-46)39.1 (30.7-49)CD811.8 (6.1-18.3)16.9 (10.8-24.9)16.6 (11.8-22.4)19.6 (11.5-26.3)20.9 (14.4-27.5)21.9 (15.7-33.8)25.4 (17.1-32.3)22.6 (16.2-28.7)21.5 (13.8-27.4)CD4/45RA^+^/CCR7^+^85.6 (74.4-89.8)73.9 (41-81.5)61.2 (25.6-78.4)56.8 (24.1-77.9)52 (26.9-74.1)57.8 (29.2-66.5)38 (15.5-59.4)40 (14.9-57)32.7 (20.9-49.1)CD4/45RA^-^/CCR7^+^7.1 (2.9-15.9)14.2 (10-18.4)14.5 (8.3-21)12.1 (8.2-17.9)13.9 (10.3-21)19 (11.6-24.7)20.7 (12.2-26.2)25.4 (15.9-34.6)33 (20.8-45.6)CD4/45RA^-^/CCR7^-^2.9 (1.7-6.1)4.7 (2.8-9)6.4 (3.4-12.4)7.4 (3.3-13.2)10.5 (4.7-22)10.6 (7.1-21.4)19.5 (10.6-34.2)18.4 (8.9-32.5)25.1 (13.9-33.6)CD4/45RA^+^/CCR7^-^5 (2.8-7)5.9 (2.3-43.9)12.3 (5.1-55.4)20.4 (5.6-52.2)20.7 (7.8-39)11.3 (6.9-34.4)18.4 (4.5-43.6)12.6 (3.9-39.2)4.9 (2-10.3)CD8/45RA^+^/CCR7^+^80.6 (72.8-85.7)63.1 (14-80.2)35.5 (8.3-64.9)24.1 (8.7-55.4)28 (11.6-46.3)29.7 (8.6-50.1)20.7 (5.5-39.7)26.1 (7-45.3)29 (13.9-43.7)CD8/45RA^-^/CCR7^+^4.5 (2.3-7.4)8.7 (4.1-15.9)4.3 (1.9-9.5)3 (1.5-5.3)2.8 (1.3-4.4)2.1 (1-4.6)1.9 (1.2-3.8)2.2 (1.5-3.9)3.4 (1.5-7.4)CD8/45RA^-^/CCR7^-^3.2 (1.4-7.2)5.7 (2.7-40.1)16.3 (5.1-41.5)18.9 (7.6-40.4)26.4 (11.9-49.8)27 (16-47.2)30.5 (20.1-44.7)26.4 (17-42.4)43.8 (25-56.9)CD8/45RA^+^/CCR7^-^11.3 (6.6-14.8)16.3 (6.6-55.4)33.7 (14-65.4)42.9 (22.2-70)38.6 (24.6-59.3)33.3 (19.5-52.5)45.6 (21.5-61)43.4 (21.8-65.7)23.3 (9-44.7)CD4/38^+^94.6 (93-97.3)93.7 (86.5-96.1)89 (71.6-94.5)81.7 (63.2-91.1)70 (44-84.8)67.8 (33.7-76.3)46.8 (24.1-66.5)36 (15-60.2)28.9 (13.8-48.2)CD4/25^+^16.7 (12.3-23.8)14.2 (11.2-20.1)14.6 (11.3-19.6)16.2 (11.3-21.4)16 (11.2-24.4)20.6 (16.9-31)26 (14.3-37.8)35.4 (20-48.8)52 (34.4-63.8)CD8/38^+^90.4 (83.2-94.5)95 (83.5-97.6)86.3 (67.9-96.2)74 (40.2-89.5)51.3 (19.2-85.9)40.4 (9.2-66.9)17.5 (5.4-45.7)11.7 (4.9-45)12.5 (6.3-23.6)CD8/56^+^2.1 (0.8-5.6)0.8 (0.3-1.4)1.3 (0.4-3.9)0.8 (0.3-2)1.5 (0.5-2.8)2.6 (0.9-6.1)3.7 (1.2-8)7 (2.5-14.3)10.5 (2.9-21.2)CD4/45RA^+^/27^+^90.8 (81.3-95.9)81.2 (69.8-86.3)79.5 (68.8-85.6)75.4 (64.4-83.7)72.7 (57.84-80.1)64.6 (54-73)56.5 (39.8-69.1)53.4 (37.3-67.4)39.2 (26.2-59.5)CD4/45RA^-^/27^+^9.2 (4.1-18.8)18.3 (13.6-29.6)18.9 (13.9-27.8)23.1 (15.2-30.4)26.6 (17.2-39.8)31.6 (24.5-39.4)36.3 (26-49.5)39.2 (28.2-52.7)51.8 (34.4-63.8)CD4/45RA^-^/27^-^0 (0-0)0.2 (0-0.8)0.8 (0.1-2.4)1.3 (0.4-3.4)1.6 (0.5-4.3)2.7 (1.2-6.5)6.2 (2.5-13.1)5.5 (3.2-13.3)7.2 (3-16.6)CD4/45RA^+^/27^-^0 (0-0.1)0 (0-0.3)0.1 (0-2.9)0.3 (0-1.3)0.1 (0-1.5)0.2 (0.1-0.7)0.3 (0.1-1.7)0.3 (0-1.8)0.2 (0-1.8)CD8/45RA^+^/27^+^94.9 (86-98.3)82.6 (50.8-90)66.4 (48.7-89.8)60 (30.8-87.9)61.3 (32.8-80.3)61.9 (37.9-78.9)54.4 (27.9-71.2)57.4 (41.5-71)49 (27.5-69.6)CD8/45RA^-^/27^+^4.3 (1.7-13.8)17.4 (10-47.4)19.3 (9-31.6)20.8 (9.9-44.8)23.3 (12-47.7)21.8 (13.1-36.8)32.6 (15-32.3)24.6 (15.9-35.6)30.9 (20.1-49.4)CD8/45RA^-^/27^-^0 (0-0.2)0 (0.1-3.2)4.4 (0.1-11.7)6.3 (0.2-16)4.6 (0.5-15.7)5.4 (1-17.1)9.6 (2.8-22.3)6.6 (2.2-13.2)5.3 (2.3-15.4)CD8/45RA^+^/27^-^0 (0-0.4)0.1 (0-1.7)1.5 (0-11.5)5.6 (0-18.3)4.9 (0.3-15.6)4.9 (0.6-19.8)9.4 (2.1-25.8)6.6 (2.2-19.4)7.4 (1.4-24.2)Total CD4/45RA^+^90.8 (81.5-95.9)81.3 (69.8-86.3)80 (69.1-85.7)75.9 (64.9-83.9)72.8 (57.9-81.1)64.6 (55.7-73.6)56.8 (43.5-70.4)53.7 (38.6-67.8)40.2 (26.3-60.8)Total CD8/45RA^+^95.4 (86.1-98.3)82.6 (51.2-90)76 (55-90.4)75.6 (41.4-88.3)70.4 (45.7-86)68.7 (47.2-82.4)65.6 (42.3-80)68 (53.3-79.2)59.3 (43.8-75.6)[^2]

TABLE IIICell-subset counts of peripheral blood lymphocytes in healthy Brazilian individualsCells/mm^3^Cord blood (53)0-3 months (51)3-6 months (50)6-12 months (53)1-2 years (50)2-6 years (55)6-12 years (50)12-18 years (50)Adults (51)Lymphocytes4260 (2442-7656)5380 (3908-7610)5670 (3860-9020)5510 (3720-8426)4845 (3245-6981)3210 (2210-5804)2645 (1937-3563)2355 (1687-2990)2030 (1350-2750)CD31565.4 (798.3-3107.7)3410.9 (2497.2-5241.6)3350.4 (1975.6-5308.9)3322.6 (2093.1-5054.5)3105.7 (1906.9-4313.9)2075.6 (1498.4-3815.7)1838.1 (1260.4-2610.1)1486.2 (1088.1-2087.9)1344.4 (849.1-1963.3)CD19568.9 (279.6-1220.7)1084.9 (531.6-1718.2)1795.3 (954.7-2596.4)1381.5 (888.1-2720)1122.7 (648.8-2072.3)640.9 (328.2-1079.5)385 (236.2-646.1)355.4 (203-574.8)237.5 (124.2-415.9)CD3^-^/16^+^56^+^667.5 (281.5-2097.5)502 (255.5-1025.4)379.5 (198.7-731)415.6 (163.7-800.6)317.9 (153-702.9)268.3 (134.6-600.8)241.1 (130.7-520.5)228.3 (116.2-443.7)235.7 (137-567.8)CD41140.3 (486.8-2283.8)2281.1 (1685.5-3417.5)2248.4 (1357.8-3374.6)2065.2 (1360.9-3265.5)1619.9 (957.2-2727.1)1177.8 (786.2-2085.5)858.4 (566.4-1292.5)847.3 (639.5-1278.5)812.9 (477.5-1140.8)CD8433.5 (237.5-977.5)876.9 (485.4-1615.3)880.6 (522.5-1798.3)1108 (559.5-1802.5)1029.9 (563.3-1753.2)730.1 (452.3-1700.5)629.3 (390.8-1010.6)486.6 (332-774.2)418 (211.7-724.6)CD4/45RA^+^/CCR7^+^929.3 (427.6-1849.3)1592.9 (825.5-2535.9)1301.7 (529.5-2578.5)1130 (366.2-2100.3)857.6 (290.8-1634.8)679.7 (286.8-1275.5)299.9 (103.1-651.2)304.1 (112-579.9)255 (107.7-497.5)CD4/45RA^-^/CCR7^+^67.5 (24.3-234.5)321.4 (208.6-460.5)295.7 (167.6-505.2)247.1 (130.8-430.4)232.6 (123.8-433.9)235.4 (136.1-436.1)156.8 (90.1-268.7)238.9 (132.1-314.8)246.1 (159.8-416.7)CD4/45RA^-^/CCR7^-^30.4 (14.1-84.7)108.8 (59.8-199.6)154.2 (69.7-273.4)159.1 (73.7-293.7)179.7 (59.9-335.4)150 (86.3-262.6)170.1 (96.9-310.9)152 (76.7-298.6)179.4 (107.6-276.7)CD4/45RA^+^/CCR7^-^57.4 (19.5-118.7)142 (51.4-855.7)289.2 (117.1-1222.6)515.1 (98.6-980.8)286.5 (93.8-741.3)166.4 (74-405.1)127.1 (38.7-380.6)96.8 (28.1-354.2)35.2 (13.3-98.8)CD8/45RA^+^/CCR7^+^348.3 (181.4-774.8)425.2 (192.8-850.9)325.3 (93.6-719.8)307.6 (55.6-582.5)267.4 (101-565.7)221.4 (71-538.2)132.5 (34.8-281.7)114.9 (37.8-248.5)121.7 (50.3-247.5)CD8/45RA^-^/CCR7^+^18.2 (9.3-42.3)70.7 (32.3-152.3)40.3 (13.5-106)29.9 (13.5-60.8)26.9 (12.5-46.7)15.9 (6.7-46.5)13.7 (7.54-21.9)11.8 (6.4-20.8)14.7 (6-41)CD8/45RA-/CCR7^-^13.8 (6.3-33.2)49.9 (18.1-595.6)127.7 (35.9-553.5)200.4 (51.3-652.3)243.3 (76.2-564.8)203.8 (76.5-563.8)201.1 (102.3-339.8)134.7 (61-241.3)176 (76.4-341.5)CD8/45RA^+^/CCR7^-^47.1 (22.2-132.6)140.2 (55.4-489.3)313.4 (124-707.2)450.3 (136.6-915.1)405.3 (196.9-756.6)248.5 (122.3-671.8)262.5 (129.8-513.2)203.2 (99.2-447.7)95.8 (25.1-214.9)CD4/38^+^1049.2 (457.3-2183.7)2129.4 (1496.1-3262.6)1883.1 (1144.1-3133.4)1604.6 (1013-2633)1022.5 (531.4-2006.7)795.1 (345.8-1430.4)422 (159-634.5)344.6 (102.3-633.9)211 (94.1-520)CD4/25^+^173.2 (86.9-395.1)349.7 (246.5-529)309.2 (238.2-485.3)325.9 (203.3-534.7)253.2 (0-394)258.1 (103.5-411.2)186.3 (0-311.6)297.8 (169.4-432.6)339.3 (236.7-681.1)CD8/38^+^379.3 (202.4-868.2)821.1 (442.4-1469.1)767.4 (372.2-1558.5)730.5 (355.2-1305.7)467.3 (100.3-912.9)272.7 (56.6-1013.2)127 (28.2-332.2)81.5 (22.4-233.3)47.4 (19.8-132)CD8/56^+^9.4 (2.9-31.2)6.5 (2.3-15.5)10 (3-44.2)9.5 (2.8-26.1)13.2 (4.8-31.1)17.3 (5.9-48.4)20.8 (4.9-56.7)33.8 (13.6-66.2)48.2 (11-80.6)CD4/45RA^+^/27^+^967.4 (346.6-2104.3)1815.4 (1312.6-2865.9)1692.1 (1083.4-2787.1)1507.7 (951.3-2587)1183.7 (408-2167.4)783.5 (459.9-1485.3)465.6 (272.3-859.1)454.8 (245.9-681.7)295.1 (122.2-572.6)CD4/45RA^-^/27^+^100.6 (27.1-253.6)416.1 (307.3-652.7)385.5 (297-614.9)445.5 (306.8-775.5)441.1 (264.2-680.3)369.8 (261.6-614.1)318.8 (249.9-452)343.1 (220.8-463.3)350.4 (231.6-573.2)CD4/45RA^-^/27^-^0 (0-0)5.8 (0.7-15.7)15.1 (3.6-41.6)26.3 (8.1-66.8)26.2 (6.4-62.5)32.2 (14.1-86.4)49.2 (26-116.8)51.8 (27.2-112.2)47.3 (23.2-123.9)CD4/45RA^+^/27^-^0 (0-0.4)0.5 (0-7.3)1.5 (0-64.1)6.9 (0.4-30.5)2 (0-18.9)2.6 (0.7-18.3)2.5 (0.4-14.4)2.2 (0.3-14.1)1.2 (0.2-18.5)CD8/45RA^+^/27^+^413 (226.6-925.8)673.8 (357.8-1092)644.1 (340.2-1132)570.5 (394-965.3)541.2 (201.6-941.1)408.4 (260.6-1059.7)365.6 (162.4-585.4)277.9 (165.2-475.8)188.2 (97.6-366.7)CD8/45RA^-^/27^+^20 (7.5-75)142.5 (58.5-617.8)168.1 (66.1-488.3)212.8 (75.8-881.3)219.9 (86.9-642.9)164.7 (85.3-406.9)169.2 (88.7-294.6)120.4 (59.4-201.2)137.4 (56-229.7)CD8/45RA^-^/27^-^0 (0-0.8)0.8 (0-37.1)32.3 (0.3-157.5)73.7 (1.1-255.7)40.3 (1.9-205)51 (6.1-169.5)62.4 (20.5-185.7)34.3 (9.3-77.7)21.3 (7.6-83.1)CD8/45RA^+^/27^-^0 (0-1.3)0.7 (0-18.8)21.2 (0-142.1)63.3 (0-251.5)54.1 (0.9-195.5)39.3 (4-252.6)54.3 (8.2-247.6)34.1 (6.4-99.6)27.1 (6-107.5)Total CD4/45RA^+^1007.9 (418.4-2114.8)1814.4 (1254-2854.8)1672 (1015.3-2771.5)1514 (970.3-2619)1246.2 (509.3-2187.4)772.9 (460.1-1530.5)473.9 (276.9-860.5)470.8 (257.6-683.3)303.5 (137.8-574.5)Total CD8/45RA^+^413 (227.3-925.8)673.4 (334.8-1083.7)650.3 (341.8-1234.9)696.2 (414.2-1164.8)657.9 (347.2-1033.6)485.6 (279.2-1062.4)440.8 (226.3-775.4)319 (190.7-551.6)242.3 (141.7-416.4)[^3]

During the first two years one observes an increase in absolute numbers of CD4^+^ T, CD8^+^ T and B lymphocytes, with a subsequent reduction in numbers from two years on for CD4^+^ T and CD8^+^ T and from six months on for B cells. NK cell numbers, in contrast, show a progressive decrease from birth and stabilise around the two-six year age strata.

With respect to T cell differentiation, there is a progressive decline in naïve T cells, but to a variable extent depending on the cell markers utilised (CD45RA/CCR7, CD45RA/CD27 or CD45RA). CD38 expression shows a faster decrease in CD8^+^ T cells than in CD4^+^ T cells. CD25 expression in CD4^+^ T cells increases only in percentage from the two-six year age strata on.

The CD56^+^ T cell subset percentage is stable up to the one-two year strata and increases from then on.

Results from the present study were compared with data from PACTG P1009 ([@B19]). Parameters compared were those that were tested by both studies within age strata from zero-three months to 12-18 years. They were: total lymphocyte, CD3^+^ T cell, CD4^+^ T cell, CD8^+^ T cell, B cell and NK cell counts ([Fig. 2](#f02){ref-type="fig"}), CD4^+^ T cells and CD8^+^ T cells were also compared by percentage and absolute values of naïve subsets (CD45RA^+^) and percentage of CD38^+^ cells ([Fig. 3](#f03){ref-type="fig"}).

Fig. 2: total lymphocyte, CD3+ T cell, CD4+ T cell, CD8+ T cell, B cell and natural killer (NK) cell counts in American children and adolescents from Pediatric AIDS Clinical Trials Group P1009 (PACTG P1009) study and from Brazilian children and adolescents distributed in similar age strata. Data are presented in median values for each age stratum, with 95% confidence interval (CI) shown for the Brazilian cohort. Study data are considered statistically different if median values from PACTG P1009 study are not included in the 95% CI of the Brazilian cohort. m: months; y: years.

Fig. 3: CD4+ T and CD8+ T cells in American children and adolescents from Pediatric AIDS Clinical Trials Group P1009 (PACTG P1009) study and in Brazilian children and adolescents distributed in similar age strata. Cells are analysed according to percentage and absolute values of naïve subsets (CD45RA+) and percentage of CD38+ cells. Study data are considered statistically different if median values from PACTG P1009 study are not included in the 95% confidence interval of the Brazilian cohort. m: months; y: years.

Brazilian CD4^+^ T cell numbers were lower than those from the PACTG P1009 ([@B19]) up to adolescence. Naïve CD4^+^ and CD8^+^ T cell percentages were also lower in Brazilian children, but percentages were comparable to the American study in older children and adolescents. CD38 expression on CD4^+^ and CD8^+^ T cells, in contrast, showed an intense reduction among Brazilian children and adolescents with a progressive difference when compared to individuals from the PACTG P1009 ([@B19]).

DISCUSSION
==========

We have assessed the distribution of lymphocyte subsets in healthy Brazilian neonates, infants, children, adolescents and adults. Individuals were not separated according to different race-ethnic groups due to the very mixed race characteristic of the Brazilian population. Demographic data showed a predominantly breastfed population with very rare (0-11%) exclusively formula-fed children.

Total lymphocyte, CD3^+^ T cell, CD8^+^ T cell, B cell and NK cell numbers showed similar values in age strata as depicted by [@B19] when assessing an American population with predominantly African and Hispanic backgrounds. CD4^+^ T cell counts, in contrast, were lower than [@B19] values up to the 12-18 year age range when values were then comparable.

Brazilian median cord blood values/mm^3^ were also lower than Ethiopians' with respect to CD3^+^T (1,565 vs. 2,640), CD4^+^ T (1,140 vs. 1,816) and CD8^+^ T cells (433 vs. 730). In contrast, total lymphocyte (4,260 vs. 3,714), B (569 vs. 528) and NK cell numbers (668 vs. 668) were comparable to Ethiopians' ([@B23]).

When compared with 39 British term infants at six-eight weeks of life, our data from the zero-three month age range showed low total lymphocytes (5,380 vs. 5,902), CD3^+^ T cells (3,411 vs. 4,098), CD4^+^ T cells (2,281 vs. 2,946) and B cells (1,085 vs. 1,481), but similar CD8^+^ T cells (877 vs. 971) and higher NK cells (502 vs. 277) in the Brazilian cohort ([@B2]).

[@B10], studying a Ugandan population, found that the decline in CD4^+^ and CD8^+^ T cells extended throughout childhood and adolescence, which is different from other western studies ([@B19]).

Other studies performed in African countries have noted low CD4^+^ T cell numbers in comparison to western countries. That was the case for [@B18], who stratified children from birth to six years in a similar way as [@B19] and our group. CD4^+^ T cells/mm^3^ were very close to our median results (cord, 1,552; 0-3 months, 2001; 3-6 months, 2,133; 6-12 months, 2,252; 1-2 years, 1,667; 2-6 years, 1,289). Another study performed in Malawi also showed low CD4^+^ T cell numbers among children compared to [@B19], but similar CD4^+^ T cell numbers among adults ([@B13]). In contrast, [@B1] evaluated a Sudanese population and found that low CD4^+^ T cells were present even in adults.

When CD4^+^ and CD8^+^ T cell subsets from our Brazilian group were assessed using CD45RA and CCR7 markers, naïve cells (CD45RA^+^CCR7^+^) were lower for all age strata both in percentage and absolute values when compared with [@B19] data using CD45RA and CD62L markers.

We have also studied CD4^+^ and CD8^+^ T cell subsets using CD45RA and CD27 markers. Naïve cells defined as CD45RA^+^CD27^+^ showed higher percentages than CD45RA^+^CCR7^+^naïve cells.

However, when CD45RA^+^ naïve cells were compared to [@B19] data, both percentages and absolute values for CD8^+^ T cells were lower for all age strata that were available for comparison. When CD4^+^ T cells were analysed in the same way, the percentage of naïve cells were similar from the two-six year range onwards and absolute values were similar to Shearer's from the six-12 year stratum onwards.

The activation marker available for comparison in the literature was mainly CD38. Our results showed a steady decline in positive cells from birth through adulthood, much in accordance with what was found by [@B14] and much lower than those reported by [@B19] for both CD4^+^ and CD8^+^ T cells.

In Thailand, researchers also observed different CD38 expression on CD8^+^ T cells when compared with Caucasians; Thai HIV-negative individuals had twice the CD38 expression of Caucasians ([@B21]).

[@B22] in Burkina Faso, Africa, noted different expression of CD38 on CD8^+^ T cells among healthy individuals. The authors hypothesised that environmental exposure may influence peripheral blood T cell activation. In their study, adults from a rural setting had higher expression of CD38 than those from an urban setting. In their opinion, both the expression of activation markers and the distribution pattern of T cell differentiation subsets may be a surrogate parameter for environmentally-driven immune senescence.

The peculiar CD38 expression in the Brazilian cohort was probably the most striking of our results, because lower levels persisted until adulthood in comparison with [@B19]. CD38 is a multifunctional ectoenzyme that uses nicotinamide adenine dinucleotide (NAD) as a substrate to generate second messengers. It was identified as one of the main cellular NADases in mammalian tissues and appears to regulate cellular levels of NAD in multiple tissues and cells. NAD participates in multiple physiological processes, such as insulin secretion, control of energy metabolism, neuronal and cardiac cell survival, airway constriction, asthma, aging and longevity ([@B5]). CD38 is a powerful disease marker for human leukaemias and myelomas, is directly involved in the pathogenesis and outcome of chronic lymphocytic leukaemia ([@B12]) and is a marker of immune activation in HIV infection ([@B27]).

In line with the influence of dietary habits on the development of the immune system, formula-fed infants evaluated at the age of four months had higher absolute counts of CD4^+^ CD38^+^ T cells than breastfed infants ([@B17]). The fact that lower CD4^+^ CD38^+^ T cell counts were found in breastfed children supports the enhancing effect of breastfeeding on lymphocyte maturation and may explain the low CD38 expression on T cells from Brazilian children.

The other possible concern refers to CD4^+^ T cell values: they were statistically lower than [@B19] up to the six-12 year age range. This finding may lead to a misclassification of Brazilian children as immunocompromised if the Centers for Disease Control and Prevention, Division of Pediatric Human Immunodeficiency Virus classification is used. Indeed, some individuals within the three-six months, six-12 months, one-two years and two-six years age ranges would be classified as "evidence of moderate suppression" (category 2) if we consider the 1994 revised classification system for HIV infection in children less than 13 years of age based on CD4^+^ T cell numbers ([@B4]). However, even Shearer et al.'s absolute values would have some children in the two-six year age range classified as "evidence of moderate suppression" (category 2) if the same Pediatric HIV classification from [@B4] was employed.

Interestingly, older age strata tend to vary less among different studies. These findings suggest that the immune system matures in different patterns in diverse populations, probably due to diverse genetic backgrounds, but also due to varied antigenic stimuli during infancy and childhood. This is especially relevant currently as the environmental influence is noted on the differentiation of the immune system ([@B20]). Unfortunately, not all studies subdivide samples into similar age ranges, which makes comparisons between studies more difficult.

Moreover, cells are assessed in varied ways, for instance, with respect to differentiation, increasing the problem of comparison between studies. Standardising immunophenotyping is the first step to allow a comparison between results from different research groups ([@B11]). However, in an effort to better understand the immune system, one needs to establish what the limits between health and disease are in different settings and age strata.

In summary, our results are consistent with previous reports suggesting that various lymphocyte subsets show similarities across different populations, but different patterns of cell populations are also present. CD4^+^ T cell counts are probably the most frequently reported divergent parameter.
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[^1]: NA: not applicable; NC: data not collected; SD: standard deviation.

[^2]: median values are shown with 10th and 90th percentiles in parenthesis.

[^3]: median values are shown with 10th and 90th percentiles in parenthesis.
